Medical Equipment Monthly Deals Analysis: April 2013 - M&A and Investment Trends - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/20894/Medical-Equipment-Monthly-Deals-Analysis:-April-2013---M&A-and-Investment-Trends/

Medical Equipment Monthly Deals Analysis: April 2013 - M&A and Investment Trends

Summary

GlobalData's "Medical Equipment Monthly Deals Analysis: April 2013 - M&A and Investment Trends" report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the medical equipment industry. The report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, segments and geographies. Additionally, the report provides information on the top financial advisory firms in the medical equipment industry.

Data presented in this report is derived from GlobalData’s proprietary in-house deals database and primary and secondary research.

Scope

- Analyze market trends for the medical equipment/medical devices market in the global arena 
- Review of deal trends in anesthesia and respiratory devices, cardiovascular devices, dental devices, diabetes care devices, diagnostic imaging, drug delivery devices, endoscopy devices, ENT devices, healthcare IT, hospital supplies, in vitro diagnostics, nephrology and urology devices, neurology devices, opthalmic devices, patient monitoring, surgical equipment, and wound care management segments
- Analysis of M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships in the medical equipment market
- Summary of medical equipment deals globally in the last six months
- Information on the top deals that took place in the medical equipment market
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa
- League Tables of financial advisors in M&A and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs
- Review the financial metrics, such as operating profit ratio, P/E ratio, and EV/EBITDA on mergers and acquisitions

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the medical equipment industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2013 in Pharmaceuticals - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/20900/Partnerships,-Licensing,-Investments-and-M&A-Deals-and-Trends-for-April-2013-in-Pharmaceuticals/

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2013 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for April 2013 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena. 
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Nuclear Energy Quarterly Deals Analysis: M&A and Investment Trends – Q1 2013 - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/15954/Nuclear-Energy-Quarterly-Deals-Analysis:-M&A-and-Investment-Trends-%E2%80%93-Q1-2013/


Nuclear Energy Quarterly Deals Analysis: M&A and Investment Trends – Q1 2013

Summary

GlobalData's "Nuclear Energy Quarterly Deals Analysis: M&A and Investment Trends – Q1 2013" report is a reliable source of essential data and analysis of mergers and acquisitions (M&As) and financing in the nuclear energy industry. The report provides detailed information on M&As, equity/debt offerings, private equity (PE), venture financing and partnership transactions registered in the nuclear energy industry in Q1 2013. The report offers detailed comparative data on the number of deals and deal values in the last five quarters segregated into deal types, segments, and geographies. Besides, the report furnishes information on the top PE, venture capital (VC), and advisory firms in the nuclear energy industry. 

GlobalData derived the data presented in this report from proprietary in-house deals database, and through primary and secondary research.

Scope

- Analyze market trends for the nuclear energy market in the global arena
- Review of deal trends in uranium mining & processing, nuclear power generation, and nuclear energy equipment & services markets.
- Analysis of M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships in the nuclear energy industry
- Summary of nuclear energy deals globally in the last five years
- Information on the top deals that took place in the nuclear energy industry
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa
- League Tables of financial advisors in M&A and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the power industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Annual Deal Report - Foodservice - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/14978/Annual-Deal-Report---Foodservice/

Product Synopsis:
The 'Annual Deal Report: Foodservice' provides a review and understanding of mergers and acquisitions (M&As), capital raising, partnering deals, and agreements entered into by Foodservice companies during 2012.

Introduction and Landscape
Why was the report written?
Using this report, dealmakers will effectively and efficiently gain an insight into the deal activity throughout the year.